Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells
Zipeng Xie, Fang Wang, Lingqiang Lin, et al.
Cancer Letters (2020) Vol. 495, pp. 200-210
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
Mieczysław Dutka, Rafał Bobiński, Tomasz Francuz, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5811-5811
Open Access | Times Cited: 67
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
Nabil V. Sayour, Á. Paál, Pietro Ameri, et al.
European Heart Journal (2024) Vol. 45, Iss. 14, pp. 1224-1240
Open Access | Times Cited: 17
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
Mohamed S. Dabour, Mina Y. George, Mary R. Daniel, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 2, pp. 159-182
Open Access | Times Cited: 15
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Kai‐Fan Tsai, Yung‐Lung Chen, Terry Ting-Yu Chiou, et al.
Antioxidants (2021) Vol. 10, Iss. 8, pp. 1166-1166
Open Access | Times Cited: 77
Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy
Changzhen Ren, Kaiqiang Sun, Yanda Zhang, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 74
SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma
Wei Wu, Zhenghao Zhang, Doudou Jing, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 6
Open Access | Times Cited: 39
Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential
Min Sun, Jilei Sun, Wei Sun, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 9
Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension
X.H. Chen, Xing Yu, Guili Lian, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116505-116505
Open Access | Times Cited: 7
Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application
A. M. Abdelhamid, Sameh Saber, Mahmoud E. Youssef, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 145, pp. 112455-112455
Open Access | Times Cited: 40
SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways
Yan Wang, Longyan Yang, Lin Mao, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 36
Novel methotrexate long-acting system using ambroxol coating and hydroxypropyl methylcellulose encapsulation for preferential and enhanced lung cancer efficiency
Samaa Abdullah, Najla Altwaijry, Meaad Alnakhli, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0314941-e0314941
Open Access
Advances in sodium-glucose transporter protein 2 inhibitors and tumors
Jiaqi Wang, Wenyong Yang
Frontiers in Oncology (2025) Vol. 15
Open Access
SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis
Dianyun Ren, Yan Sun, Dan Zhang, et al.
Cancer Letters (2021) Vol. 519, pp. 277-288
Closed Access | Times Cited: 37
Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review
Kristy T. K. Lau, Lui Ng, Jason W.H. Wong, et al.
Reviews in Endocrine and Metabolic Disorders (2021) Vol. 22, Iss. 4, pp. 1121-1136
Closed Access | Times Cited: 35
Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK
Kenji Shoda, Shohei Tsuji, Shinsuke Nakamura, et al.
Cellular and Molecular Neurobiology (2022) Vol. 43, Iss. 2, pp. 879-892
Closed Access | Times Cited: 22
Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
Zofia Wicik, A Nowak, Joanna Jarosz-Popek, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 22
Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy
Mina Y. George, Mohamed S. Dabour, Eman Rashad, et al.
Antioxidants (2024) Vol. 13, Iss. 6, pp. 671-671
Open Access | Times Cited: 4
Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond
Massimiliano Camilli, Marcello Viscovo, Luca Maggio, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 4
Regulation of CyR61 expression and release by 3-mercaptopyruvate sulfurtransferase in colon cancer cells
Kelly Ascenção, Bassma Lheimeur, Csaba Szabó
Redox Biology (2022) Vol. 56, pp. 102466-102466
Open Access | Times Cited: 20
Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications
Zahra Vaziri, Kiarash Saleki, Cena Aram, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115686-115686
Open Access | Times Cited: 11
Galloyl-oligochitosan nano-vehicles for effective and controlled propolis delivery targeting upgrading its antioxidant and antiproliferative potential
Khulud Mohammed Alshehri, Ehab M. Abdella
International Journal of Biological Macromolecules (2024) Vol. 270, pp. 132283-132283
Closed Access | Times Cited: 3
Dapagliflozin suppressed gastric cancer growth via regulating OTUD5 mediated YAP1 deubiquitination
Kaijie Ren, Xueni Wang, Rulan Ma, et al.
European Journal of Pharmacology (2024), pp. 177002-177002
Open Access | Times Cited: 3
Empagliflozin: a potential anticancer drug
Wenwen Wu, Yanyan Wang, Jun Xie, et al.
Discover Oncology (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy
Rosalinda Madonna, Serena Barachini, Stefania Moscato, et al.
Vascular Pharmacology (2021) Vol. 142, pp. 106949-106949
Closed Access | Times Cited: 21
Cancer related safety with SGLT2-i and GLP1-RAs: Should we worry?
Marco Gallo, Matteo Monami, Alberto Ragni, et al.
Diabetes Research and Clinical Practice (2023) Vol. 198, pp. 110624-110624
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top